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Abstract
Despite their high prevalence, lack of understanding of the exact
pathophysiology of the functional gastrointestinal disorders has restricted us to
symptomatic diagnostic tools and therapies. Complex mechanisms underlying
the disturbances in the bidirectional communication between the gastrointestinal
tract and the brain have a vital role in the pathogenesis and are key to our
understanding of the disease phenomenon. Although we have come a long way
in our understanding of these complex disorders with the help of studies on
animals especially rodents, there need to be more studies in humans, especially to
identify the therapeutic targets. This review study looks at the anatomical
features of the gut-brain axis in order to discuss the different factors and
underlying molecular mechanisms that may have a role in the pathogenesis of
functional gastrointestinal disorders. These molecules and their receptors can be
targeted in future for further studies and possible therapeutic interventions. The
article also discusses the potential role of artificial intelligence and machine
learning and its possible role in our understanding of these scientifically
challenging disorders.
Key words: Functional gastrointestinal disorders; Idiopathic bowel syndrome; Gut-brain
axis; Microbiome-gut-brain axis; Machine learning; Artificial intelligence
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: The multifactorial nature of functional gastrointestinal disorders makes the
diagnosis challenging. The identification of pathogenic microbiome signatures,
combined with demographical, immunologic and neuroimaging findings can be encoded
into machine learning algorithms which may help identify trends and patterns that can be
studied to further our understanding of these disorders. These patterns can help
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determine the causality or can guide further research.
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INTRODUCTION
Functional  gastrointestinal  disorders  (FGIDs)  are  a  highly  prevalent  group  of
disorders diagnosed solely by symptomatology as there is a lack of understanding of
the underlying structural or chemical abnormalities. The main symptoms described
by patients with FGIDs include abdominal pain, dyspepsia, regurgitation, bloating,
constipation, diarrhea, incontinence, problems in the passage of food or stool, or any
combination of these symptoms. Different mechanisms have been understood to play
a role in pathogenesis including disturbance in motility, altered mucosal and immune
function,  visceral  hypersensitivity,  disturbance  in  gut  microbiota,  and  altered
processing of visceral signals in the central nervous system (CNS). Common FGIDs
include gastroesophageal reflux disease (GERD), functional dysphagia, functional
dyspepsia, gastroparesis, irritable bowel syndrome (IBS), functional constipation,
diarrhea, and fecal Incontinence.
It has been well established that patients with FGIDs, along with having symptoms
related to the gastrointestinal tract, have co-existing psychosocial symptoms such as
stress, anxiety and depression and thus a biopsychosocial model has been proposed
for  FGIDs as  depicted in  Figure 1[1].  The bidirectional  communication pathways
between the gut and the brain, involved in the pathogenesis of FGIDs, are collectively
known as  the gut-brain axis[2].  This  communication occurs  through a number of
neuronal pathways and is modified by environmental and anatomical factors such as
hypothalamus-pituitary  axis,  limbic  system,  autonomic  nervous  system,  and
endocrine system. The gut microbiota has recently emerged as a possible influencer of
the axis and has seized the much-needed attention of researchers.
Although it has been a widely held belief that human cells are outnumbered by
microorganisms by a ratio of 1:10 recent literature shows that the ratio is closer to1:1[3].
This, however, does not diminish the important role of microbiota in our bodies. The
microbiota, living in harmony with the human tissues, has a number of synergistic
roles. Although the exact composition of the microbiota may differ among individuals
as  each  individual  has  their  own  microbiome  signature,  its  functional  role  in
homeostasis and development is ubiquitous to all humans. From helping in digestion,
to protecting against pathogenic microorganisms, the gut microbiota has played an
important role in maintaining immunity and homeostasis. Recently, studies have
shown that  one of  the main inputs  to  the gut-brain axis  comes from microbiota,
leading to the coining of the term ‘microbiome-gut-brain axis’[4].
This article reviews the important anatomical aspects of the gut-brain axis in order
to  discuss  the  underlying  molecular  mechanisms  that  may  have  a  role  in  the
pathogenesis of FGIDs. It further discusses the different factors that may influence the
gut-brain axis and can be used in the future as possible therapeutic targets. The article
also looks at the potential new approaches such as the use of artificial intelligence and
machine learning to help advance our understanding of these complex disorders.
ANATOMICAL CORRELATES OF GUT AND BRAIN
CONNECTIONS IN RELATION TO FGIDS
The  brain  and  gut  communicate  continuously  through  a  number  of  complex
pathways involving the enteric nervous system (ENS), the autonomic nervous system
(ANS), the hypothalamus-pituitary axis (HPA), and the central nervous system (CNS)
as  shown  in  Figure  2[2].  Each  pathway  is  highly  integrated  and  regulated  by
interrelational neuronal and neurohumoral factors.
FGIDS: Enteric nervous system and central nervous system interaction
The ENS is responsible for the intrinsic innervation of the GI tract and consists of two
plexuses. The outer plexus, called myenteric plexus, is involved in the regulation of
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Figure 1
Figure 1  The biopsychosocial model for functional gastrointestinal disorder. The figure illustrates the
interaction of psychosocial factors, environmental factors and disturbances in gut-brain axis with functional GI
disorders. Early life stress events combined with psychosocial state of an individual determines the symptomatology
and quality of life of individuals. Adopted from ROME IV[1].
smooth  muscles  controlling  the  gut  movements  such  as  peristalsis.  The  inner,
submucosal,  plexus  is  responsible  for  secretion  and  absorption[5].  The  ENS  is
modulated by the extrinsic innervation coming from the ANS and the CNS. The ANS
consists  of  sympathetic  (splanchnic)  nerves  and  parasympathetic  (vagal-sacral)
nerves. The somatic nervous system controls the striated muscles of the proximal
esophagus and the external anal sphincter. In CNS, the highly integrated gut-brain
communication axis is mainly controlled by the limbic system which receives input
from the ENS through the ANS and is modulated by higher cortical areas[2].
The limbic system consists of the amygdala, hypothalamus, medial thalamus and
the anterior cingulate cortex (ACC). It is primarily concerned with the regulation of
behavior, emotions, arousal, memory and motivation. It is also partly responsible for
the  modulation  of  the  visceral  organs  by  providing  input  through a  number  of
hemostatic  mechanisms.  The visceral  region,  also  known as  ‘visceral  brain’,  lies
specifically in the hypothalamus which is a central component of the limbic system[6].
The amygdala is responsible for emotional and stressful responses and drives other
areas such as the prefrontal cortex for execution of complex functions. Functional
brain imaging using magnetic resonance imaging (MRI) has shown that damage to
the amygdala results in an alteration in stress responses such as flat affect seen in
schizophrenia patients[7]. The damage may also lead to inhibition of social interaction
and emotional conditioning[7].  The amygdala also consolidates memories with the
help of emotional stimuli[6].
There are two pathways involved in the processing of the emotional input. A direct
pathway,  which  processes  crude  information,  is  called  the  thalamo-amygdala
pathway. It is chiefly responsible for rapid, unconditioned fear response without the
intervention of the cortex. The thalamo-cortico-amygdala pathway, on the other hand,
allows  for  a  slower,  conditioned  response  by  more  complex  processing  of  the
emotional stimuli (Figure 3)[8].
The anterior  cingulate  cortex (ACC) has  a  central  role  in  the thalamo-cortico-
amygdala pathway. The ACC detects the conflict between the current emotional state
and any new stimulus that can incite a new affective or motivational response. It
relays information to the pre-frontal cortex (PFC) where further processing of the
input takes place and the decision is  made about how to respond to the stimuli.
Functional Magnetic Resonance Imaging (fMRI) has highlighted that the perigenual
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Figure 2
Figure 2  Schematic representation of different factors modulating the gut-brain axis. The microbiota and
central nervous system interact in a bidirectional relationship bridged by the gut-brain axis. This axis is also
influenced by Immune system, enteric nervous system, hypothalamic-pituitary axis, and vagus nerve. CNS: Central
nervous system; ENS: Enteric nervous system; HPA: Hypothalamic-pituitary.
ACC becomes activated in response to an emotional input. In situations of conflict, the
PFC  cortex  further  activates  different  regions  of  the  cortex  which  helps  in  the
decision-making process  for  deriving the appropriate  response to  the presented
stimuli. Patients with depression have been often shown to have abnormalities in the
left PFC and may also express difficulties in executive functioning.
Interaction between ANS and the Vagus nerve in FGIDs
Disturbance in the ANS has often shown to correlate with flare-up of IBS symptoms[9],
however, no definite pattern of ANS activation has emerged. Some studies suggest
activation or inhibition of parasympathetic innervation while others suggest increased
or  decreased sympathetic  activity.  Some authors  suggest  that  there  is  a  specific
pattern in IBS depending on diarrhea or constipation-predominant symptoms but the
reproducibility  of  such  patterns  has  been  inconsistent  due  to  methodological
limitations or limited power to allow for a specific pattern to emerge[2,10,11]. The role of
ANS in psychiatric disorders, acute stress and pain is relatively more evident[2,12].
The Vagus nerve is responsible for relaying visceral information to the brain via
parasympathetic  pathways.  It  contains  both  sensory  and  motor  pathways  and
provides innervation to the entire gut except the distal colon, rectum and internal anal
sphincter which are innervated by the sacral (parasympathetic) ganglion. The afferent
fibers carry sensations to the nucleus of solitary tract (NTS) and mediate both noxious
stimuli, such as dull pain, non-noxious sensations such as hunger and nausea[13]. The
motor fibers travel from nucleus ambiguus (NA) and the dorsal motor nucleus (DMN)
in the brain stem to the ENS and regulate physiological functions such as motility and
secretion. A number of vasovagal reflexes such as enterogastric and gastrocolic also
modulate GI function[14].
The higher cortex influences the vagus nerve as well by modulating the vagus
nerve  nuclei  in  the  brainstem.  The  NTS  receives  sensory  information  from  the
abdominal viscera and relays it to the higher brain regions[15]. Projections from NTS
also terminate into the hypothalamus and limbic system which may explain why
there  is  an  altered  perception  of  visceral  pain  in  individuals  with  psychiatric
symptoms.  Vagal  motor  nuclei  receive  input  from  brain  regions  such  as  the
hypothalamus, area postremia, and inferior-anterior cingulate cortex. These networks
assimilate sensory input coming from NTS and formulate appropriate downstream
responses via nucleus ambiguus[14].
The HPA axis in FGIDs
The  Corticotropin-releasing  hormone  (CRH)  seems  to  affect  the  motility  and
sensitivity of the gut,  however,  it  is  not completely understood if  it  is  a primary
response or occurs due to another stimulus[16]. Studies have reported increased levels
of  CRH  in  IBS  patients  and  increased  baseline  levels  in  patients  with  anxiety
disorders, however, the replication of these results has often been inconsistent.
The  role  of  different  emotional  states  in  FGID has  been  well  established.  For
example, volunteers who were subjected to different stressors showed alterations in
their GI function[17-19]. Studies on rodents have shown that when these animals are put
under stress, their brain undergoes neurochemical changes[20,21] along with augmented
visceral sensitivity[22].
In one study, women with IBS showed altered cellular immune response compared
to control subjects. This in part is thought to be mediated by adrenergic pathways but
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Figure 3
Figure 3  The pathways involved in emotional response. The thalamo-amygdala pathway is responsible for
unconditioned fast response without the input from the cortex. The thalamo-cortico amygdala pathway provides input
for a complex, conditioned response due to input from the cerebral cortex.
does not essentially include the activation of the HPA axis[23]. Dinan et al[24] showed
that patients with IBS had increased response to CRH and expressed increased levels
of inflammatory hormone Interleukin-6 and Interleukin-8. Another study involving
twenty-one IBS patients and 18 controls, showed that IBS patients had increased HPA
axis responsiveness, however, this overstimulation was more likely due to traumatic
events early in life which are common in patients with IBS[25].
Neuroimmune interactions in FGIDs
The ENS, also called the ‘second brain’, is capable of independent functioning without
intermediation from the ANS. It consists of an estimated 108 neurons arranged in two
ganglionic plexuses[26]. There is a complex interdependent relationship between the
gut immune system and the ENS. Physiological functions of the gut such as motility,
absorption and secretion are all very sensitive to subtle changes in this fine balance
between  the  immune  system  and  the  nervous  system[27].  For  example,  immune
activation due to local inflammation can have a diffuse effect on GI motility[28].
Patients with post-infectious IBS (PI-IBS) have been studied for understanding the
role of the immune system in FGIDs. The incidence of PI-IBS is reported between 5%
and 32%[29].  The risk of developing PI-IBS increases many times if  the presenting
illness is  predominantly diarrheal  and lasts  for  more than 3 wk[30].  Additionally,
hypochondriasis and stressful life event at the initial illness doubles the risk of PI-IBS,
providing further evidence for the involvement of the immune system[31].
Ascending and descending pain pathways and FGIDs
Diffuse, visceral pain is the most common symptom and hallmark feature in a number
of  patients  with  FGIDs.  Significant  pain  or  abdominal  disturbance  leads  to
impairment in social functioning which may prompt hospital visits.
While  the  neurological  pathways  and  underlying  molecular  mechanisms  for
somatic pain have been well studied, the understanding of the visceral pain remains a
daunting challenge. The altered perception of pain can occur due to an abnormality in
the visceral pain pathways and can occur at the level of the nociceptors, neuronal
pathways, thalamus, and corticolimbic signaling pathway[32].
Pain receptors in the viscera mainly respond to chemical stimulation, mechanical
stimulation such as distension or stretching, and ischemia or infection[33]. Initial insult
leads  to  a  release  of  inflammatory mediators  such as  prostaglandins,  adenosine
triphosphate, histamine, serotonin, and bradykinin. These inflammatory mediators
cause pain sensitization by acting on a number of receptors, prominent among which
are transient receptor potential vallinoid (TRPV) receptors 1 and 4, voltage-gated
sodium calcium channels (VGSCs) and protease-activated receptors 2 (PAR(2)).
TRPV1 and 4 receptors mainly sense mechanical stimulus. TRPV1 is particularly
implicated in patients with FGIDs as it has been shown to play a role in visceral pain
hypersensitization. In rat models, Akbar et al[34] have shown that there was a 3.5-times
increase in the concentration of TRPV1 receptors in IBS patients compared to healthy
individuals.  Reciprocally,  TRPV1 antagonists  have  been  shown to  decrease  the
visceral pain sensitivity in rat models and may present a possible therapeutic target[35].
The TRPV4 receptors and PAR (2) receptors work closely and may become activated
by serine proteases. These proteases are found in increased concentration in patients
with  FGIDs.  Antagonizing  these  receptors  reduces  nerve  discharge  possibly
preventing the sensitization[36].
The afferent pain fibers, which originate in viscera, relay to the dorsal horn of the
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spinal cord and then ascend through the spinal cord to the midbrain and cortex.
Biochemically active agents such as substance P, glutamate, aspartate and vasoactive
intestinal peptides are released in nerve terminals of the dorsal column of the spinal
cord.  These  nociceptive  signals  ascend  in  two  major  ascending  pathways:  the
spinothalamic and the spinoparabrachial  tracts.  Studies using positron emission
tomography (PET) have helped in outlining the functioning of these pathways. The
mid-cingulate portion of the ACC has often been stimulated in patients with visceral
hypersensitivity compared to healthy individuals. This is also the same area which is
involved in the perception of fear and obnoxiousness[37].
The afferent signal is processed and modulated by the higher cortex which then
transmits it to the perigenual ACC. This signal further travels down to the spinal cord
via opioidergic, serotoninergic and noradrenergic systems to dorsal column of the
spinal  cord and modulates the afferent  pain signals[38].  As the same limbic areas
control emotional and cognitive signals, it is thought that the downstream inhibitory
pain signals may be altered by the attentional and emotional state of an individual.
ROLE OF MICROBIOTA-GUT-BRAIN AXIS IN FGIDs
Microbiota has recently emerged as a key player in the gut-brain axis. This interaction
between the brain and the microbiota has led to the recognition of a new term called
‘microbiota-gut-brain  axis’[39].  This  interaction is  bidirectional,  meaning that  the
disturbance in the complex community of microbiota (dysbiosis) can affect the brain
and vice-versa.  The  underlying signaling  mechanisms for  these  communicating
networks between gut flora and the gut-brain axis have been of special interest to
researchers and pharmacists who are seeking potential therapeutic interventions.
The microbiota-gut-brain axis has been mainly studied in rodent models and two
approaches  have been used.  In  the  first  one,  germ-free  mice  are  compared with
healthy mice with normal gut-flora to look for changes in desired characteristics or
behaviors. Although the germ-free model has certain limitations, it is an excellent tool
that has been used over the years to help advance our understanding of the axis. In
the other approach, wide-spectrum antibiotics are used to induce changes in the
composition of microbiota and then these treated mice are compared with untreated
mice to look for the desired characteristics.
The evidence for bidirectional communication comes from studies that have shown
that early life stress can alter the composition of gut microbiota, highlighting the role
of the brain as an influencer on the gut through the gut-brain axis[22]. Reciprocally,
healthy mice showed anxiety-like behaviors after the administration of pathogenic
bacteria such campylobacter jejni or Citrobacter rodentium[40,41], suggesting an inverse role
of the role microbiome on the brain.
Dysbiosis
Every human has a unique and subject specific community of microorganisms. This
fingerprint of microorganisms, which is an ecosystem in homeostasis, develops early
in life  and may undergo some modifications but  by and large,  it  remains  stable
throughout  life[42].  The  modifications  may  be  due  to  competition  from  other
microorganisms  or  pressure  from  the  host[43].  Microbiota  participates  in  the
modulation of intestinal motility, blood flow, secretions, immunity and perception of
visceral signals[44]. Therefore it is speculated that dysbiosis plays an important role in
the pathogenesis and symptoms perception of FGID.
Studies demonstrate that the germ-free mice show developmental changes from
mice with normal microbiota. These changes may resemble features of functional GI
diseases[45,46]. Conversely, recolonization of these mice can restore some functions such
as mucosal immunity[47].
On the contrary, when these mice are infected with pathogenic microorganisms,
they may produce features that may resemble symptoms of IBS and in some cases
IBD[48].  Other  mechanisms that  have  been  suggested  include  gut  distention  and
alterations in secretion and motility of the GI tract. These changes seem to arise from
the production of gas and fatty acids by the bacterial flora influencing the microbiota
to host signaling[49].
Dysbiosis is seen in different GI diseases including celiac disease, IBS and IBD[50,51].
Although dysbiosis seems to be an important denominator in patients with FGIDs, no
specific  symbiotic  signature  has  been  identified.  This  could  be  due,  in  part,  to
different  sites  used  for  sampling  and  varying  techniques  used  to  analyze  the
cultures[52-54].
Dysbiosis  can  also  upset  the  HPA  axis;  for  example,  compared  to  mice  with
standard  microbiota,  germ-free  mice  produce  increased  levels  of  the
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adrenecorticotrophin (ACTH) and other stress hormones[55]. Conversely, on restoring
the  intestinal  flora  of  germ-free  mice,  there  is  decreased  production  of  stress
hormones and a partial reversal of anxiety-like behaviors[55]. Germ-free mice also have
decreased levels  of  brain-derived neurotrophic  factor  (BDNF)  due  to  decreased
expression of NMDA receptors[56]. These proteins are involved in the differentiation
and growth of new neurons[55,57].
Other studies have also highlighted the role of microbiota in the development of
the brain and gut through a number of complex pathways. Thus it is thought that
dysbiosis  could be one of  the causes of  behavioral  traits  associated with anxiety
disorders[56]. Table 1 represents the different factors that that modify gut-brain-axis
and play a role in the pathophysiology of FGIDs.
MODULATION OF THE GUT-BRAIN AXIS IN FGIDS
Our understanding of the pathophysiology of FGIDs is still developing, as currently
there is a dearth of studies on human subjects and the challenge is to test whether
findings in animals are translatable to humans. Only a few controlled studies have
been done in human subjects which have highlighted the modifying role of probiotics,
antibiotics, diet and fecal microbiota transplantation.
Role of probiotics in FGIDs
Probiotics contain live microorganisms that, when ingested, can have a beneficial
effect on the host. Probiotics have found application in a number of gastrointestinal
and immune system disorders[58] and their evaluation as a possible therapeutic target
in FGIDs is one trending in the research community. One thing is certain that the role
of  probiotics  cannot  be  overlooked  as  has  been  shown in  numerous  studies  on
animals and humans as highlighted below.
Studies on rodents have shown that the administration of probiotics leads to a
reduction in visceral pain sensitization[59,60]. Mckernan et al[60] demonstrated that 14 d
oral gavage of Bifidobacterium infantis showed reduced colorectal distension, increased
pain threshold and delayed first  pain behavior.  Bercik et  al[61]  infected mice with
Trichuris muris, a noninvasive parasite, and treated with etanercept, budesonide, or
specific probiotics.  They found that infected mice showed anxiety-like behaviors
secondary to colonic inflammation.  There was decreased BDNF messenger RNA
(mRNA) in the hippocampus. The mice also showed immune system changes with
increased Circulating tumor necrosis factor-α and interferon-γ. The administration of
Bifidobacterium longum restored the normal behavior to some extent and normalized
BDNF mRNA levels but did not affect immune system changes[61]. The study shows
that the role of probiotics may be selective in that they may affect the gastrointestinal
system but spare other systems.
Studies in human subjects are relatively limited. In a randomized controlled study
in  patients  with  IBS,  the  intake  of  Bifidobacterium  lactis  significantly  reduced
abdominal  distension  and  resulted  in  an  overall  improvement  of  symptoms[62].
O’Mahony et al[63] demonstrated that 8 weeks intake of Bifidobacterium infantis led to an
improvement of IBS symptoms and restoration of normal interleukin10:interleukin 12
ratio in blood.
The evidence for the use of probiotics has been mounting but specific strains and
molecular targets remain to be determined.
FGIDs and role of antibiotics
Antibiotics  can  rapidly  reduce  the  diversity  of  the  organisms  allowing  certain
pathogenic  bacteria  to  wreak  havoc.  Antibiotics  have  been  shown  to  influence
psychiatric behaviors in individuals being treated for different reasons. Mohle et al
observed that in comparison to non-treated mice, stressful behavior and poor memory
and poor hippocampal  functioning was evident  in  those who were treated with
antibiotics. The same mice, when treated with probiotics, showed improvement in
these cognitive symptoms[64]. Verdú et al[59] showed that the administration of oral
antimicrobials in mice led to mucosal inflammation and visceral hypersensitivity due
to  increased  substance  P  expression  in  the  enteric  nervous  system  (ENS).  This
inflammatory  response  was  alleviated  by  the  administration  of  Lactobacillus
paracasei[59].
FGIDs and role of diet
Diet can improve the symptoms of FGID in two ways by modulating the gut-brain
axis:  improving psychological symptoms and by having a probiotic-like effect[65].
Magnusson  et  al[66]  studied  changes  in  the  behavior  of  mice  and  their  gut  flora
composition following the administration of different diets. Analysis showed that
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Table 1  Different factors that influence the brain - Gut interaction in functional gastrointestinal disorders
Nature of link Evidence Comments
Dysbiosis Kassinen et al[82]; Tojo et al[83]; Chassard et al[84];
Cryan et al[85]
Disturbance in the complex community of
microbiota seems to influence gut-brain axis by
modulating neuroendocrine, neuroimmunal and
visceral sensory system.
Altered mucosal secretions Mazmanian et al[86]; Xue et al[87] Secretion is modulated by complex interaction of
intrinsic and extrinsic factors acting on gut
mucosa. Dysregulation of the epithelial cells due
to autonomic reactivity may lead to 5-HT release
contributing to altered secretion
Disturbance in motility Randich et al[13]; Dass et al[88]; Barbara et al[89] Products of metabolism of gut bacteria, such as
short-chain fatty acids modulate enteric system
and influence the rate of gut transit
Visceral hypersensitivity O'Mahony et al[22]; Akbar et al[34] Patients with IBS have been found to have an
increased concentration of pain-sensing receptors
such as TPRV1 compared to the controls.
Altered processing of visceral signals Lemann et al[90]; Mertz et al[91] There is increased activation of certain cerebral
areas in IBS patients compared to the controls.
Altered processing of the visceral pain in the
central nervous system has been a recurring theme
in many studies.
Immune dysfunction Chadwick et al[92]; Dinan et al[24]; Keely et al[93] Patients with prolonged Infectious diarrhea are
much more prone to developing IBS. Also,
biopsies of patients with IBS have shown
increased immune cells in the mucosa[92].
Psychological disturbances Creed et al[17]; Gwee et al[94]; Drossman et al[95];
Monnikes et al[2,12]
Patients with FGIDs have co-existing psychosocial
symptoms such as stress, anxiety and depression
and thus a biopsychosocial model has been
proposed for FGIDs
Early life stress O'Mahony et al[22]; Bailey et al[96] Early life-stress can alter the composition of gut
microbiota
5-HT: 5-hydroxytryptamine; FGID: Functional Gastrointestinal diseases; IBS: Inflammatory bowel disease; TRPV1: Transient receptor potential vallinoid 1.
Erysipelotrichales was increased in the gut of mice which were fed high fat diet and
Lactobacillus was increased in the mice which were given high sucrose diet. The diet
influenced the cognitive behavior of the mice and these changes correlated with the
composition of different bacteria in the gut of these mice[66]. Li et al[67] observed that
compared to control mice, the mice which were fed a meat-containing diet showed
better microbial diversity, improved memory and less stressful behavior. Similar
findings were reported by a number of other studies suggesting that diet can have a
profound effect on the composition of microbiota in mice and can improve or worsen
anxiety-like  behaviors[68,69].  However,  due  to  difficulties  in  analyzing  the  gut
microbiota, the reproducibility of these results in human subjects requires continued
efforts with new research approaches.
POTENTIAL USEFULNESS OF FUNCTIONAL AND
STRUCTURAL NEUROIMAGING IN FGIDS
The  complex  nature  of  the  psychosocial  interactions  that  underlie  the
pathophysiology of the FGID has always eluded researchers. The plethora of studies
highlighting the role of gut-brain axis in the development of symptoms in FGID has
not been met with effective strategies that can use this relationship to develop key
diagnostic  tools  and  therapeutic  agents[70].  Studies  have  mainly  focused  on  the
biochemical interactions that play a role in the gut-brain axis but in vivo studies have
been  limited  so  far  due  to  lack  of  noninvasive  neurophysiological  techniques.
Recently,  the utilization of new techniques such as functional brain imaging has
allowed  an  objective  assessment  of  the  axis.  Table  2  summarises  the  different
techniques that have been used to study the gut-brain axis.
The field of neuroimaging has rapidly evolved recently and provides a promising
new approach to the complex interactions of peripheral nerves and the brain. Since
pain and discomfort are the main symptoms in people with FGID, studies have been
limited to peripheral pain reflex pathways and ANS responses. It is thought that the
treatment models that have worked on rodents and failed in human subjects might be
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Table 2  Methods used to study brain - Gut interaction in functional gastrointestinal disorders
Link to be tested Name of the test Evidence Comments
Microbiota-gut-brain axis
Germ-free mice Abrams et al[45] This has been the most widely used
technique to study the gut-brain axis.
Germ-free mice are compared with
healthy to look for changes in desired
characteristics or behaviors
Antibiotic-treated mice Verdú EF et al[59] Antibiotics are used to induce
changes in the composition of
microbiota and then these treated
mice are compared with untreated
mice to look for the desired
characteristics. Antibiotics are useful
for selectively eliminating certain
bacteria from the gut, allowing the
growth of other strains.
Mice treated with probiotics Mohle et al[64] Once germ-free mice have been
studied, they can be injected with
probiotics to establish the reciprocity
of the relationship that has been
studied.
The interactions between visceral, peripheral and central pathways
Functional MRI (fMRI) Tillisch et al[72]; Aziz et al[73]; Mayer et
al[75], and Labus et al[76]
fMRI measures the changes in
oxygenated and deoxygenated
hemoglobin where oxygenated
hemoglobin denotes the group of
neurons that have increased activity.
They are useful in studying the
complex relationship between
visceral stimuli and brain response.
PET imaging Tillisch[72] PET imaging has the advantage of
probing a particular receptor by
developing a radiolabeled ligand.
This important feature can be used to
assess specific receptor activities
during pain and stress response in
control and FGID patients.
Structural MRI (sMRI) Seminowicz et al[77] Whole and regional brain images
using sMRIs have been used to study
differences between individuals with
FGIDs and control groups
FGIDs: Functional gastrointestinal diseases; MRI: Magnetic resonance imaging; PET: Positron emission tomography.
due to the increased CNS modulation of the subcortical pathways[71]. Neuroimaging
offers a non-invasive method to evaluate the interactions between the visceral and
central pathways and the effect of psychological symptoms on these pathways.
Functional brain imaging in FGIDs
Functional brain imaging assesses brain function in response to different visceral
stimuli.  There are two main modalities  that  are used for imaging brain function
namely,  functional  magnetic  resonance  imaging  (fMRI)  and  positron  emission
tomography (PET)[72].
MRI  has  been  the  focus  of  attention  for  experts  from a  number  of  fields.  For
example, psychiatrists have used fMRI to gain insight into complex psychological
disorders such as obsessive-compulsive disorders and schizophrenia. Functional MRI
(fMRI) measures the changes in oxygenated and deoxygenated hemoglobin where
oxygenated hemoglobin denotes the group of neurons that have increased activity[73].
Studies that have looked at the complex relationship between visceral stimuli and
brain response have frequently produced inconsistent results which are often difficult
to interpret. The only consistent finding that has been elicited so far after a meta-
analysis of a number of studies has shown that the rectal distension in IBS patients is
linked to the stimulation of anterior cingulate gyrus. Compared to the controls, the
areas of the brain for emotional arousal in anterior cingulate gyrus were differentially
activated in patients with IBS. The same meta-analysis also showed that the history of
abuse and stressful life events synergistically correlated with the activation of these
same brain areas[74].  The anterior cingulate gyrus has also been implicated in the
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modulation of the autonomic nervous system, maintenance of homeostasis and has
been shown to have been affected by disturbances in emotions and the gut-brain
axis[75]. Despite the limited results so far, fMRI remains an important modality and
ongoing research promises to understand the functional neural networks. Studies are
aiming to examine the entire functioning networks rather than focusing on particular
regions. Two main functioning networks that have been the focus of scientists are the
emotional  arousal  network  (including  amygdala  and anterior  cingulate  cortical
subregions) and hemostatic afferent network (anterior mid cingulate cortex, posterior
insula,  thalamus,  dorsal  pons)  as  previous  studies  have suggested an increased
activity in these networks in patients with FGIDs[75,76].
The use of positron emission tomography (PET) imaging in FGIDs has been limited
due to high costs,  difficulty in engineering relevant ligands and the widespread
availability  of  fMRIs.  However,  PET  imaging  has  the  advantage  of  probing  a
particular receptor by developing a radiolabeled ligand. This important feature can be
used to assess specific receptor activities during pain and stress response in control
and FGID patients. The technique may also attract pharmacists who want to study the
distribution and response of a particular therapeutic agent targeted at a receptor and
comparisons can be made between the placebo and intervention groups[72].
Structural brain imaging in FGIDs
Whole  and regional  brain  images  have  been  used  to  study differences  between
individuals  with  FGIDs  and  control  groups.  It  has  also  been  useful  in  baseline
imaging and response to  treatment.  Structural  brain images use high resolution
structural MRI (sMRI) to measure cortical thickness and gray matter density which
can be compared between different groups. The role of structural brain imaging in
FGID  has  been  not  explored  in  great  detail  compared  to  psychiatric  disorders.
Structural  changes  in  the  brain  have  been  seen  in  individuals  with  a  history  of
childhood trauma.  Although the  structural  changes  may  seem ‘fixed’,  dynamic
changes have been seen in patients under conditions such as learning, illness and
stress. The few studies that have been carried out on FGID patients using structural
images have indicated that there is decreased grey matter density in certain areas of
the brain such as the medial prefrontal and ventrolateral prefrontal cortex, striatum
and thalamus; while there may be increased density in the anterior cingulate and
orbitofrontal cortex. Interestingly, controlling for stressors showed that there was no
significant difference in the grey matter density between the patients with FGIDs and
controls[77].
WHAT DOES THE FUTURE HOLD?
There is still a long way to go to understand the exact role of the neural, immunologic,
biochemical and other pathways in the gut-brain axis and the FGIDs. There is also a
need to these translate findings of animal studies to human subjects using multi-
population randomized controlled trials. The role of microbiota has opened exciting
new avenues and its exact role needs to be explored with the identification of the
individual  specific  strains  that  may  help  to  tailor  the  probiotic  therapy.  The
neuroimaging combined with immunologic and biochemical findings can be used to
develop patterns of pathogenesis and for guiding further research.
The application of machine learning to medical diagnosis
The  multifactorial  nature  of  FGID  can  make  diagnosis  a  challenging  and  time-
consuming task. Machine learning and artificial intelligence (AI) are important tools
that  can  potentially  be  employed  to  help  with  the  diagnosis  of  FGID  and  aid
healthcare professionals and researchers in combing through the plethora of available
patient data to identify trends and investigate causal relationships between the trends.
Once causality has been established it could shed light on the mechanisms behind the
pathogenesis  of  FGID  and  help  researchers  understand  how  the  gut-brain-
microbiome axis functions.
The use of machine learning processes such as inductive learning to define rules
that govern diagnostic algorithms in different plant species has been shown to be
effective and at times superior to rules obtained by human experts. It has often been
proven  to  outperform rules  defined  by  human experts  even  as  early  as  1980[78].
Inductive learning algorithms can learn from examples or prototypes and come up
with diagnostic rules for the examples provided[79].
In recent times, the availability of large databases of digitized patient data provides
a  unique  opportunity  for  machine  learning algorithms to  analyze  and interpret
databases to identify correlations between different symptoms, imaging findings and
biochemical findings. The algorithms then develop classifiers by pattern recognition
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which can be used as a framework to develop a diagnostic algorithm or improve
existing algorithms by incorporating new classifiers into them or testing the reliability
of established classifiers. A machine learning program can be used in such a way to
diagnose conditions based on clinical findings and investigations[80].  For example,
Kukar et al successfully used a machine learning approach to successfully diagnose
patients  with  ischemic  heart  disease  using  an  algorithm employing  a  step-wise
diagnostic approach. The algorithms improved the detection of positive and negative
cases by 6% compared to manual detection by the clinicians[81].
The advantages of machine learning algorithms
Autonomy and automation: Most machine learning algorithms are autonomous to
variable degrees and the process of obtaining knowledge is largely automated which
makes these methods of learning and data analyses highly efficient. The algorithms
also look for trends in the data that the researchers may not have considered and
therefore provides more knowledge than conventional methods of data analysis over
a significantly smaller amount of time[80].
Dealing with incomplete or noisy data:  Machine learning algorithms are highly
adaptable and consequently very good at dealing with and accounting for missing
and/or noisy data which is a very common occurrence in electronic patient records[80].
Explanation ability:  Most  algorithms have the  ability  to  explain  the  trends and
qualifiers that they identify. These explanations can be very valuable for guiding
further research[79,80].
Transparency: The knowledge generated and the explanations behind the decisions
made by most algorithms is transparent to the physicians and therefore the reasoning
of the algorithm is easy to understand.
Future studies on the gut-brain-microbiome axis need to evaluate the feasibility of
using  machine  learning  programs to  study patient  data  to  identify  correlations
between the clinical findings, demographic information, neuroimaging findings, lab
tests and gut microbiome analysis to develop newer and more reliable diagnostic
criteria.
Role of gut microbiota
An aspect of the gut-brain-microbiome axis which requires further investigation is the
gut microbiota and its effects on the pathogenesis of FGID. Future studies need to
look at both the bacterial and fungal parts of the microbiome to ascertain the extent to
which  the  gut  microbiota  plays  a  role  (if  at  all)  in  FGID as  there  is  a  dearth  of
literature on this topic.
CONCLUDING
The gastrointestinal tract and nervous system are constantly communicating with
each other  in  a  bidirectional  relationship  which  is  influenced by the  autonomic
nervous system, immune system, hypothalamic-pituitary axis and gut microbiota.
Understanding the molecular and biochemical mechanisms disturbing this complex
network of communication is key to our understanding of the pathophysiology of the
functional GI diseases. Studies in rodents have provided us with substantial evidence
about the underlying mechanisms, however, there is a need to translate these findings
in human subjects to successfully identify the therapeutic targets.
The identification of pathogenic microbiome signatures in individuals combined
with demographical data, serological findings and neuroimaging findings can be
encoded  into  machine  learning  algorithm  which  may  help  identify  trends  and
patterns that can be potentially overlooked by humans.
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